575 related articles for article (PubMed ID: 26551667)
21. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
[TBL] [Abstract][Full Text] [Related]
22. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
23. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
24. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.
Curiel-Lewandrowski C; Yamasaki H; Si CP; Jin X; Zhang Y; Richmond J; Tuzova M; Wilson K; Sullivan B; Jones D; Ryzhenko N; Little F; Kupper TS; Center DM; Cruikshank WW
J Clin Invest; 2011 Dec; 121(12):4838-49. PubMed ID: 22080865
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the novel Sezary lymphoma cell line BKP1.
Boudjarane J; Essaydi A; Farnault L; Popovici C; Lafage-Pochitaloff M; Beaufils N; Berda-Haddad Y; Lacroix R; Nicolino-Brunet C; Le Treut T; Zattara H; Gabert J; Kahn-Perlès B; Costello R
Exp Dermatol; 2015 Jan; 24(1):60-2. PubMed ID: 25314094
[TBL] [Abstract][Full Text] [Related]
26. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
[TBL] [Abstract][Full Text] [Related]
27. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
28. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
Karenko L; Hahtola S; Päivinen S; Karhu R; Syrjä S; Kähkönen M; Nedoszytko B; Kytölä S; Zhou Y; Blazevic V; Pesonen M; Nevala H; Nupponen N; Sihto H; Krebs I; Poustka A; Roszkiewicz J; Saksela K; Peterson P; Visakorpi T; Ranki A
Cancer Res; 2005 Sep; 65(18):8101-10. PubMed ID: 16166283
[TBL] [Abstract][Full Text] [Related]
29. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
30. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic findings in cell lines from cutaneous T-cell lymphoma.
Kaltoft K; Hansen BH; Thestrup-Pedersen K
Dermatol Clin; 1994 Apr; 12(2):295-304. PubMed ID: 8045039
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
[TBL] [Abstract][Full Text] [Related]
33. [Histoclinical and immunohistochemical diagnosis of cutaneous lymphomas].
Maryniak RK; Jankowska-Konsur A
Pol J Pathol; 2011 Dec; 62(4 Suppl 3):s1-23. PubMed ID: 22693733
[No Abstract] [Full Text] [Related]
34. Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.
Jones CL; Degasperi A; Grandi V; Amarante TD; ; Mitchell TJ; Nik-Zainal S; Whittaker SJ
Sci Rep; 2021 Feb; 11(1):3962. PubMed ID: 33597573
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic insights into cutaneous T-cell lymphoma.
Tensen CP; Quint KD; Vermeer MH
Blood; 2022 Jan; 139(1):15-33. PubMed ID: 34570882
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
37. Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
Gallardo F; Bertran J; López-Arribillaga E; González J; Menéndez S; Sánchez I; Colomo L; Iglesias M; Garrido M; Santamaría-Babí LF; Torres F; Pujol RM; Bigas A; Espinosa L
Leukemia; 2018 Oct; 32(10):2211-2223. PubMed ID: 29511289
[TBL] [Abstract][Full Text] [Related]
38. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
Lamprecht B; Kreher S; Möbs M; Sterry W; Dörken B; Janz M; Assaf C; Mathas S
Br J Dermatol; 2012 Aug; 167(2):240-6. PubMed ID: 22384858
[TBL] [Abstract][Full Text] [Related]
39. Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
[TBL] [Abstract][Full Text] [Related]
40. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]